A detailed history of Alliancebernstein L.P. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Alliancebernstein L.P. holds 1,217,705 shares of BPMC stock, worth $110 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,217,705
Previous 1,139,002 6.91%
Holding current value
$110 Million
Previous $123 Million 8.29%
% of portfolio
0.04%
Previous 0.04%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$84.1 - $120.5 $6.62 Million - $9.48 Million
78,703 Added 6.91%
1,217,705 $113 Million
Q2 2024

Aug 14, 2024

SELL
$85.18 - $108.78 $5.5 Million - $7.03 Million
-64,590 Reduced 5.37%
1,139,002 $123 Million
Q1 2024

May 14, 2024

SELL
$73.17 - $99.79 $11.3 Million - $15.4 Million
-154,391 Reduced 11.37%
1,203,592 $114 Million
Q4 2023

Feb 14, 2024

SELL
$43.96 - $92.84 $6.12 Million - $12.9 Million
-139,271 Reduced 9.3%
1,357,983 $125 Million
Q3 2023

Nov 14, 2023

SELL
$46.9 - $66.0 $5.34 Million - $7.52 Million
-113,927 Reduced 7.07%
1,497,254 $75.2 Million
Q2 2023

Aug 15, 2023

SELL
$42.2 - $66.37 $5.51 Million - $8.67 Million
-130,623 Reduced 7.5%
1,611,181 $102 Million
Q1 2023

May 15, 2023

BUY
$37.97 - $50.0 $7.81 Million - $10.3 Million
205,649 Added 13.39%
1,741,804 $78.4 Million
Q4 2022

Feb 14, 2023

BUY
$41.06 - $66.48 $5.22 Million - $8.45 Million
127,048 Added 9.02%
1,536,155 $67.3 Million
Q3 2022

Nov 15, 2022

SELL
$49.93 - $77.7 $4.41 Million - $6.86 Million
-88,298 Reduced 5.9%
1,409,107 $92.8 Million
Q2 2022

Aug 15, 2022

SELL
$45.23 - $70.15 $614,494 - $953,057
-13,586 Reduced 0.9%
1,497,405 $75.6 Million
Q1 2022

May 13, 2022

BUY
$54.1 - $110.08 $554,308 - $1.13 Million
10,246 Added 0.68%
1,510,991 $96.5 Million
Q4 2021

Feb 14, 2022

BUY
$94.25 - $115.99 $10 Million - $12.4 Million
106,541 Added 7.64%
1,500,745 $161 Million
Q3 2021

Nov 10, 2021

SELL
$80.98 - $109.47 $650,674 - $879,591
-8,035 Reduced 0.57%
1,394,204 $143 Million
Q2 2021

Jul 30, 2021

BUY
$82.78 - $101.0 $237,578 - $289,870
2,870 Added 0.21%
1,402,239 $123 Million
Q1 2021

May 06, 2021

BUY
$90.71 - $108.28 $10 Million - $12 Million
110,564 Added 8.58%
1,399,369 $136 Million
Q4 2020

Feb 08, 2021

SELL
$92.08 - $124.48 $3.13 Million - $4.23 Million
-34,008 Reduced 2.57%
1,288,805 $145 Million
Q3 2020

Nov 12, 2020

BUY
$66.45 - $92.7 $10.1 Million - $14.1 Million
151,989 Added 12.98%
1,322,813 $123 Million
Q2 2020

Aug 13, 2020

BUY
$57.09 - $79.27 $4.88 Million - $6.78 Million
85,477 Added 7.88%
1,170,824 $91.3 Million
Q1 2020

May 14, 2020

SELL
$48.11 - $82.22 $1.88 Million - $3.22 Million
-39,126 Reduced 3.48%
1,085,347 $63.5 Million
Q4 2019

Feb 18, 2020

BUY
$66.73 - $82.59 $4.13 Million - $5.12 Million
61,955 Added 5.83%
1,124,473 $90.1 Million
Q3 2019

Nov 14, 2019

BUY
$72.9 - $101.41 $1.54 Million - $2.14 Million
21,148 Added 2.03%
1,062,518 $78.1 Million
Q2 2019

Aug 14, 2019

BUY
$73.54 - $97.8 $3.62 Million - $4.82 Million
49,241 Added 4.96%
1,041,370 $98.2 Million
Q1 2019

May 14, 2019

BUY
$48.7 - $86.6 $6 Million - $10.7 Million
123,259 Added 14.19%
992,129 $79.4 Million
Q4 2018

Feb 13, 2019

SELL
$45.57 - $74.26 $7.2 Million - $11.7 Million
-157,952 Reduced 15.38%
868,870 $46.8 Million
Q3 2018

Nov 08, 2018

BUY
$58.91 - $78.32 $14.8 Million - $19.7 Million
252,028 Added 32.53%
1,026,822 $80.2 Million
Q2 2018

Aug 13, 2018

SELL
$60.96 - $101.18 $1.93 Million - $3.21 Million
-31,733 Reduced 3.93%
774,794 $49.2 Million
Q1 2018

May 14, 2018

SELL
$73.28 - $102.95 $4.63 Million - $6.51 Million
-63,240 Reduced 7.27%
806,527 $74 Million
Q4 2017

Feb 13, 2018

SELL
$62.91 - $88.32 $12.9 Million - $18 Million
-204,296 Reduced 19.02%
869,767 $65.6 Million
Q3 2017

Nov 13, 2017

BUY
$42.37 - $69.67 $45.5 Million - $74.8 Million
1,074,063
1,074,063 $74.8 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.38B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.